CEL-SCI Corporation (CVM) Balance Sheet

The current ratio of 0.60 indicates that current liabilities significantly outweigh liquid assets, suggesting a high probability of near-term liquidity stress. Investors should monitor the company's ability to secure additional financing, as the current cash balance appears insufficient to sustain operations through the next major regulatory milestone.

The asset mix is heavily skewed toward fixed infrastructure rather than liquid or revenue-generating assets. This concentration implies that the company's book value is highly sensitive to the success of the Multikine program, as these specialized assets may hold little residual value in an alternative use scenario.

The consistent decline in equity highlights the value-destructive nature of the current business model, which relies on continuous capital raises to offset operational losses. This trend suggests that existing shareholders face ongoing dilution risks as the company attempts to bridge the gap between clinical development and commercial viability.